» Articles » PMID: 33794997

An Integrative Multi-omics Approach Reveals New Central Nervous System Pathway Alterations in Alzheimer's Disease

Overview
Date 2021 Apr 2
PMID 33794997
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Multiple pathophysiological processes have been described in Alzheimer's disease (AD). Their inter-individual variations, complex interrelations, and relevance for clinical manifestation and disease progression remain poorly understood. We hypothesize that specific molecular patterns indicating both known and yet unidentified pathway alterations are associated with distinct aspects of AD pathology.

Methods: We performed multi-level cerebrospinal fluid (CSF) omics in a well-characterized cohort of older adults with normal cognition, mild cognitive impairment, and mild dementia. Proteomics, metabolomics, lipidomics, one-carbon metabolism, and neuroinflammation related molecules were analyzed at single-omic level with correlation and regression approaches. Multi-omics factor analysis was used to integrate all biological levels. Identified analytes were used to construct best predictive models of the presence of AD pathology and of cognitive decline with multifactorial regression analysis. Pathway enrichment analysis identified pathway alterations in AD.

Results: Multi-omics integration identified five major dimensions of heterogeneity explaining the variance within the cohort and differentially associated with AD. Further analysis exposed multiple interactions between single 'omics modalities and distinct multi-omics molecular signatures differentially related to amyloid pathology, neuronal injury, and tau hyperphosphorylation. Enrichment pathway analysis revealed overrepresentation of the hemostasis, immune response, and extracellular matrix signaling pathways in association with AD. Finally, combinations of four molecules improved prediction of both AD (protein 14-3-3 zeta/delta, clusterin, interleukin-15, and transgelin-2) and cognitive decline (protein 14-3-3 zeta/delta, clusterin, cholesteryl ester 27:1 16:0 and monocyte chemoattractant protein-1).

Conclusions: Applying an integrative multi-omics approach we report novel molecular and pathways alterations associated with AD pathology. These findings are relevant for the development of personalized diagnosis and treatment approaches in AD.

Citing Articles

A novel integrative multimodal classifier to enhance the diagnosis of Parkinson's disease.

Zhou X, Parisi L, Huang W, Zhang Y, Huang X, Youseffi M Brief Bioinform. 2025; 26(2).

PMID: 40062615 PMC: 11891661. DOI: 10.1093/bib/bbaf088.


Multiomics of Aging and Aging-Related Diseases.

Kiseleva O, Arzumanian V, Ikhalaynen Y, Kurbatov I, Kryukova P, Poverennaya E Int J Mol Sci. 2025; 25(24.

PMID: 39769433 PMC: 11677528. DOI: 10.3390/ijms252413671.


Integrating Molecular Perspectives: Strategies for Comprehensive Multi-Omics Integrative Data Analysis and Machine Learning Applications in Transcriptomics, Proteomics, and Metabolomics.

Sanches P, de Melo N, M Porcari A, de Carvalho L Biology (Basel). 2024; 13(11).

PMID: 39596803 PMC: 11592251. DOI: 10.3390/biology13110848.


Uncovering disease-related multicellular pathway modules on large-scale single-cell transcriptomes with scPAFA.

Huang Z, Zheng Y, Wang W, Zhou W, Zhang Y, Wei C Commun Biol. 2024; 7(1):1523.

PMID: 39550507 PMC: 11569158. DOI: 10.1038/s42003-024-07238-7.


Assessing polyomic risk to predict Alzheimer's disease using a machine learning model.

Ngai T, Willett J, Waqas M, Fishbein L, Choi Y, Hahn G Alzheimers Dement. 2024; 20(12):8700-8714.

PMID: 39511865 PMC: 11667526. DOI: 10.1002/alz.14319.


References
1.
Mateo I, Llorca J, Infante J, Rodriguez-Rodriguez E, Berciano J, Combarros O . Gene-gene interaction between 14-3-3 zeta and butyrylcholinesterase modulates Alzheimer's disease risk. Eur J Neurol. 2008; 15(3):219-22. DOI: 10.1111/j.1468-1331.2008.02059.x. View

2.
Chalikiopoulou C, Jenko Bizjan B, Leventopoulos G, Smaili K, Blagus T, Menti A . Multiomics Analysis Coupled with Text Mining Identify Novel Biomarker Candidates for Recurrent Cardiovascular Events. OMICS. 2020; 24(4):205-215. DOI: 10.1089/omi.2019.0216. View

3.
Juarez-Rebollar D, Rios C, Nava-Ruiz C, Mendez-Armenta M . Metallothionein in Brain Disorders. Oxid Med Cell Longev. 2017; 2017:5828056. PMC: 5632493. DOI: 10.1155/2017/5828056. View

4.
Miners J, Clarke P, Love S . Clusterin levels are increased in Alzheimer's disease and influence the regional distribution of Aβ. Brain Pathol. 2016; 27(3):305-313. PMC: 8029153. DOI: 10.1111/bpa.12392. View

5.
Duits F, Brinkmalm G, Teunissen C, Brinkmalm A, Scheltens P, van der Flier W . Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. Alzheimers Res Ther. 2018; 10(1):5. PMC: 6389073. DOI: 10.1186/s13195-017-0335-x. View